Increasing prevalence of cancer is supporting the growth of the global recombinant human endostatin market
North America is expected to lead
the global recombinant human endostatin market and this is attributed to the
high prevalence of cancer in the region which is creating demand for such
therapy. According to a report by the Centers for Disease Control and
Prevention (CDC), around 1,633,390 new cancer cases were reported in the U.S.
in 2015 and the number is expected to reach 1,735,350 in 2018. Also, an
increasing number of clinical trials is again expected to foster the growth of
the market.
Key
players operating in the global recombinant human endostatin market include
Pfizer Inc., Novus Biologicals, Biocon, Thermo Fisher Scientific, Yantai
Medgenn Ltd., FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd., PeproTech, Inc., Onyx
Pharmaceuticals, Inc., Genexine, Inc., Hetero., Intas Pharmaceuticals Ltd., and
Novartis AG.
A growing number of research
& development activities to recognize potential applications of recombinant
human endostatin is expected to foster the growth of the recombinant
human endostatin market. Increasing demand for cancer treatment and ongoing
studies to identify potential collagen are again fostering the growth of the
market. According to the World Health Organization (WHO), around 18.1 million
new cases of cancer were recorded in 2018, with 9.6 million deaths due to the
disease. Also, the rise in the geriatric population around the globe coupled
with the expanding pharmaceutical & biotechnology companies using
recombinant human endostatin is further projected to foster the growth of the
market.
Moreover, increasing investment
in the research &development activities based on the use of recombinant
technology is further anticipated to augment the growth of the market.
In
January 2017, the PLA General Hospital in China has undertaken a clinical phase
II study for recombinant human endostatin combination with radiotherapy for the
treatment of Hepatocellular Carcinoma (HCC). The study was estimated to
complete in December 2019.
A clinical trial is a rigorous
medical procedure intended to test an important new medical product or
procedure. The goal of such a trial is to provide evidence for or against the
effectiveness, safety, and effectiveness of medical treatment. Clinical trials
are conducted by healthcare companies to test drugs, medical devices, and other
health products. Sometimes, healthcare companies conduct both clinical trials
and consumer-based tests to determine whether a new product's benefits are
worth the cost of introducing it into the marketplace. For Recombinant Human
Endostatin, a biotechnology company called Generex has conducted an important
clinical trial.

Comments
Post a Comment